Bristol-Myers Squibb Co. has agreed to acquire ZymoGenetics, Inc. for $735 million, adding biologics for hepatitis and other diseases to its pipeline. The acquisition is part of the company’s strategy to expand its virology franchise, as well as an effort to offset expected loss of market exclusivity in the next few years for top-selling drugs, namely Plavix. Bristol-Myers Squibb chief executive officer Lamberto Andreotti said, “The acquisition gives the company full ownership of a promising ...